Here are 1-3 brief analogies for Verrica Pharmaceuticals (VRCA):

• Like a Vertex Pharmaceuticals, but entirely focused on developing breakthrough treatments for skin diseases.
• A specialized pharmaceutical company for skin conditions, similar to how Gilead Sciences focuses on antivirals.
• Imagine a smaller, prescription-focused Galderma, developing novel treatments for medical skin conditions.

• VP-102: A lead product candidate for the treatment of molluscum contagiosum, external genital warts, and common warts.
• VP-103: A cantharidin-based product candidate in development for treating plantar warts.
• LTX-315: A product candidate being developed for dermatological oncology indications through a license agreement.

Verrica Pharmaceuticals (VRCA) primarily sells to other companies (B2B model).

Based on the provided information, its major customer companies include:

• Torii Pharmaceutical Co., Ltd. (TYO: 4559): This company has a license and collaboration agreement with Verrica Pharmaceuticals for the development and commercialization of its product candidates (including VP-102) for the treatment of molluscum contagiosum and common warts in Japan.
• Lytix Biopharma AS (OSE: LTX): This company has a license agreement with Verrica Pharmaceuticals to develop and commercialize LTX-315 for dermatological oncology indications.

For its direct product commercialization efforts in the United States, Verrica Pharmaceuticals would typically sell its treatments to pharmaceutical wholesalers and distributors, which then supply pharmacies and healthcare providers. However, the provided background information does not name specific wholesaler or distributor companies as direct customers.

Jayson Rieger, Ph.D., M.B.A. - President & CEO

Dr. Rieger brings over 20 years of experience in leadership roles encompassing business development, operations, drug discovery, and product development within the life sciences industry. Prior to joining Verrica, he served as Executive Vice President of PBM Capital Group, LLC, and is also a Managing Partner with PBM Capital. His previous roles include Corporate Senior Vice President and President of the Human Therapeutics Division at Intrexon Corporation, Vice President of Research and Virginia Operations for Clinical Data, Inc., and Vice President of Lead Development at Adenosine Therapeutics, LLC.

John J. Kirby - Interim Chief Financial Officer

Mr. Kirby has over 25 years of public company accounting and finance experience, specifically with small to mid-sized public pharmaceutical companies. Before joining Verrica, he served as Chief Financial Officer for Aceragen, Inc. (formerly Idera Pharmaceuticals, Inc.), where he also held roles including Vice President of Finance and Vice President of Corporate Accounting. Earlier in his career, Mr. Kirby was Assistant Controller at Endo Pharmaceuticals, Inc., and Vice President, Chief Accounting Officer, and Corporate Controller at ViroPharma Incorporated. He began his career at KPMG, LLP in its Healthcare and Life Science Practice and was a Regional Audit Director at AstraZeneca Pharmaceuticals L.P.

Noah Rosenberg, M.D. - Chief Medical Officer

Dr. Rosenberg possesses more than 30 years of clinical and therapeutic development experience, having led multiple global drug approvals, including in dermatology. He has served as Chief Medical Officer for various public and private biotechnology companies, overseeing clinical development and medical strategy for pipeline candidates and product launches. Most recently, he was CMO at Travere Therapeutics, where he led the team responsible for the successful approval of Filspari. Dr. Rosenberg also led the development of Xepi at Medimetriks and held leadership positions at Esperion Therapeutics, Forest Research Institute, Sanofi Aventis, and Pfizer.

David Zawitz - Chief Operating Officer

Prior to his role at Verrica, Mr. Zawitz served as Executive Vice President and Secretary of PBM Capital Group, LLC since March 2021, having been with PBM Capital's legal department since 2018. Before his time at PBM Capital, he held roles of increasing responsibility with CarMax, Inc. from 2012 to 2018, including Assistant General Counsel and Assistant Secretary. Mr. Zawitz also practiced as an attorney in private practice with Bingham McCutchen LLP and McKee Nelson LLP.

Chris Chapman - Chief Commercial Officer

Mr. Chapman joined Verrica with over 25 years of commercial pharmaceutical experience and leadership, particularly in dermatology. He most recently served as Chief Commercial Officer at Dermavant Sciences, where he was instrumental in the launch of VTAMA® (tapinarof) cream. Mr. Chapman was also a key leader in the integration of the Dermavant commercial organization following its acquisition by Organon. His career also includes roles at Organon, Galderma, and Pfizer.

The key risks to Verrica Pharmaceuticals (VRCA) primarily revolve around its financial viability, the complex regulatory landscape for its product candidates, and the inherent uncertainties of clinical development and commercialization.

1. Financial Health and Going Concern: Verrica Pharmaceuticals has faced significant financial challenges, including sustained net losses, negative operating cash flow, and poor financial strength metrics, with a Z-Score indicating distress. Although the company reported increased revenue in Q4 2025 and has taken steps to reduce expenses and secure cash flow into Q1 2027, doubts persist regarding its long-term ability to fund operations without additional capital or substantial revenue growth from its products. The company's negative equity position and history of not yet achieving overall profitability highlight an ongoing risk to its financial stability.
2. Regulatory Approval and Manufacturing Dependence: The company's lead product, YCANTH (VP-102), for molluscum contagiosum, encountered multiple Complete Response Letters (CRLs) from the FDA due to deficiencies identified at contract manufacturing organization (CMO) facilities. These issues, while not always directly related to the drug product itself, caused significant delays in obtaining regulatory approval. While YCANTH has since been approved for molluscum contagiosum, the history underscores the inherent regulatory risks faced by biotechnology firms and the critical dependence on third-party manufacturers, whose compliance issues can significantly impact product development and supply for current and future pipeline candidates.
3. Clinical Trial Success and Market Adoption: Verrica's business success relies heavily on the successful completion of clinical trials for its pipeline candidates, such as VP-102 for external genital warts and common warts, and VP-103 for plantar warts. As a biotechnology firm, the company faces inherent risks associated with drug development, including the possibility of clinical trial failures. Furthermore, even upon successful approval, there is a risk that products may not achieve significant market adoption due to competition or other market factors.

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) operates in several dermatology markets with its product candidates. The addressable markets for its main products are outlined below:

• Molluscum Contagiosum (VP-102):
  • The global molluscum contagiosum market was valued at approximately USD 2.42 billion in 2024 and is projected to reach USD 3.67 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 4.75%.
  • In the United States, the molluscum contagiosum treatment market was valued at approximately USD 1.2 billion in 2023. North America holds the most significant share of the global molluscum contagiosum market.
• External Genital Warts (VP-102):
  • The global genital warts market is estimated to be valued at USD 2.1 billion in 2025 and is projected to reach USD 3.3 billion by 2035, with a CAGR of 4.8%. Another report indicates a global market size of USD 8.39 billion in 2024, projected to reach USD 14.21 billion by 2032, with a CAGR of 6.8%.
  • The market across the 7 Major Markets (7MM), which includes the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan, reached a value of USD 851.3 million in 2024 and is expected to reach USD 1,435.0 million by 2035, exhibiting a CAGR of 4.89%. The United States represents the largest market for genital warts treatment within the 7MM.
• Common Warts (VP-102):
  • The global common warts market is projected to grow from USD 826.4 million in 2025 to USD 1,177.1 million by 2035, at a CAGR of 3.6%. Other estimations place the global common warts market at approximately USD 2.13 billion in 2024, growing to USD 2.83 billion by 2029 with a CAGR of 5.8%.
  • The common warts market across the 7MM (US, EU4, UK, and Japan) reached a value of USD 784.4 million in 2024 and is expected to reach USD 1,096.1 million by 2035, with a CAGR of 3.1%. The United States represents the largest market for common warts, comprising about 50% of the total market size across the 7MM.
• Plantar Warts (VP-103):
  • While a specific, standalone market size for plantar warts is not distinctly provided, plantar warts are generally included within the broader "warts therapeutics" market, which covers common, plantar, and genital warts. The global warts therapeutics market size is projected to be USD 2145.8 million in 2025.
• Dermatological Oncology Indications (LTX-315 for basal cell carcinoma):
  • The global skin cancer treatment market was valued at USD 10.87 billion in 2024 and is expected to reach USD 19.27 billion by 2032, growing at a CAGR of 7.42%. Another source estimates the global market at USD 9.03 billion in 2025, projected to reach USD 14.98 billion by 2032 with a CAGR of 7.48%.
  • The U.S. skin cancer treatment market size was valued at USD 3.24 billion in 2024 and is expected to reach USD 5.57 billion by 2032, growing at a CAGR of 7.06%. The U.S. and Canada skin cancer dermatology market size was USD 3.15 billion in 2023 and is projected to hit around USD 5.13 billion by 2033, with a CAGR of 5.0%. North America holds a significant share of the global skin cancer therapeutics market.

Verrica Pharmaceuticals (NASDAQ: VRCA) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

1. Continued Growth and Market Penetration of YCANTH for Molluscum Contagiosum: Verrica's flagship product, YCANTH (VP-102), for the treatment of molluscum contagiosum, is a significant revenue driver. The company reported substantial increases in YCANTH net revenue and dispensed applicator units in 2025, with strong demand continuing into early 2026. Verrica is actively expanding its sales force and implementing strategic initiatives aimed at establishing YCANTH as the standard of care for molluscum contagiosum.

2. International Expansion of YCANTH for Molluscum Contagiosum: The company is expanding the reach of YCANTH beyond the U.S. Verrica's partner, Torii Pharmaceutical, launched YCANTH in Japan in February 2026, contributing to significant collaboration revenue for Verrica in 2025. Additionally, Verrica has achieved alignment with the European Medicines Agency (EMA), providing a clear regulatory path to file for YCANTH approval in the European Union without requiring additional clinical studies, which could accelerate market access in Europe.

3. Launch of YCANTH (VP-102) for Common Warts: Verrica initiated a global Phase 3 clinical development program for YCANTH (VP-102) for the treatment of common warts in December 2025, with the first patient dosed. Common warts represent a substantial market opportunity, with an estimated 22 million affected individuals in the United States alone and currently no FDA-approved prescription therapies. The company expects to initiate a second Phase 3 study in the U.S. and Japan in mid-2026. Verrica retains global commercial rights for common warts outside of Japan.

4. Advancement and Potential Launch of VP-315 for Basal Cell Carcinoma: Verrica is progressing VP-315, its novel oncolytic peptide, toward a Phase 3 program for basal cell carcinoma (BCC) in 2026. This pipeline advancement into dermatological oncology could unlock a new significant revenue stream for the company in the coming years.

Share Issuance

• Verrica Pharmaceuticals executed a private investment in public equity (PIPE) financing in November 2025, raising approximately $50 million in gross proceeds.
• This PIPE financing involved the sale of 6,499,826 shares of common stock and pre-funded warrants to purchase 5,305,164 shares, along with accompanying warrants.
• The company completed a reverse stock split at a ratio of 1-for-10 shares of common stock on July 24, 2025.

Inbound Investments

• In November 2025, Verrica Pharmaceuticals secured approximately $50 million through a private investment in public equity (PIPE) financing, anchored by Caligan Partners LP and PBM Capital.
• The company received $18 million in cash milestone payments from Torii Pharmaceutical during 2025, following an amended collaboration and license agreement for the global Phase 3 program for YCANTH for common warts.
• Verrica received a $10 million milestone payment for YCANTH approval in Japan in Q3 2025.

Capital Expenditures

• Research and development expenses for the full year 2025 were $8.9 million, showing a decrease from $11.8 million in 2024, primarily due to reduced clinical costs for VP-315, although costs associated with the Phase 3 program for common warts increased.
• Torii Pharmaceutical will fund the first $40 million of costs for the global Phase 3 program study for YCANTH for common warts, covering approximately 90% of the current budget.